BGI Genomics Co., Ltd. (SHE:300676)
China · Delayed Price · Currency is CNY 50.36
+0.06 (0.12%)
Feb 4, 2026, 3:04 PM CST
BGI Genomics Cash Flow Statement
Financials in millions CNY. Fiscal year is January - December.
Millions CNY. Fiscal year is Jan - Dec.
Fiscal Year | TTM | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 |
|---|---|---|---|---|---|---|
Period Ending | Sep '25 Sep 30, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Jan '23 Jan 1, 2023 | Jan '22 Jan 1, 2022 | Dec '20 Dec 31, 2020 |
Net Income | -799.91 | -902.69 | 92.9 | 802.77 | 1,462 | 2,090 |
Depreciation & Amortization | 469.23 | 469.23 | 436.84 | 453.07 | 370.6 | 302.33 |
Other Amortization | 85.94 | 85.94 | 47.4 | 34.61 | 25.82 | 25.89 |
Loss (Gain) From Sale of Assets | 0.63 | 0.63 | -2.76 | -0.11 | 3.88 | 4.23 |
Asset Writedown & Restructuring Costs | 193.76 | 193.76 | 9.25 | 209.24 | 102.24 | 105.02 |
Loss (Gain) From Sale of Investments | 87.41 | 87.41 | 33.07 | -388.21 | -260.29 | -153.32 |
Provision & Write-off of Bad Debts | 197.1 | 197.1 | 66.41 | 185.1 | 104.56 | 140.86 |
Other Operating Activities | -382.12 | 14.52 | 82.53 | 325.54 | 130.7 | 131.05 |
Change in Accounts Receivable | -438.84 | -438.84 | 736.49 | -1,086 | 254.15 | -471.96 |
Change in Inventory | -34.2 | -34.2 | 103.78 | 46.25 | 169.94 | -603.7 |
Change in Accounts Payable | 284.49 | 284.49 | -1,345 | -484.64 | 147.51 | 2,117 |
Change in Other Net Operating Assets | 115.5 | 115.5 | 122.81 | 22.85 | - | - |
Operating Cash Flow | -198.14 | 95.72 | 408.77 | 130.88 | 2,476 | 3,603 |
Operating Cash Flow Growth | - | -76.58% | 212.31% | -94.71% | -31.27% | 1506.52% |
Capital Expenditures | -440.71 | -529.48 | -1,236 | -1,267 | -383.52 | -301.15 |
Sale of Property, Plant & Equipment | -0.2 | 0.56 | 2.72 | 0.33 | 0.71 | 4.04 |
Cash Acquisitions | - | - | - | 5.2 | - | - |
Divestitures | - | - | - | -0.01 | 5.91 | - |
Investment in Securities | -183.99 | 116.67 | -763.71 | 569.72 | -2,069 | 431.01 |
Other Investing Activities | 66.82 | 97.83 | 246.64 | 111.31 | 153.44 | 60.08 |
Investing Cash Flow | -558.07 | -314.42 | -1,751 | -580.07 | -2,292 | 193.98 |
Long-Term Debt Issued | - | 192.8 | 251.68 | 20 | 5 | 1,289 |
Total Debt Issued | 602.38 | 192.8 | 251.68 | 20 | 5 | 1,289 |
Long-Term Debt Repaid | - | -94.96 | -78.77 | -780.21 | -690.2 | -60.42 |
Total Debt Repaid | -490.61 | -94.96 | -78.77 | -780.21 | -690.2 | -60.42 |
Net Debt Issued (Repaid) | 111.77 | 97.84 | 172.91 | -760.21 | -685.2 | 1,228 |
Issuance of Common Stock | 53.08 | 53.08 | 82.85 | - | 2,003 | - |
Repurchase of Common Stock | -780.52 | -780.52 | - | -336.74 | - | -482.32 |
Common Dividends Paid | -16.15 | -50.36 | -416.73 | -167.13 | -177.78 | -62.29 |
Other Financing Activities | 445.53 | -3.18 | -105.91 | 69.54 | -102.79 | 466.78 |
Financing Cash Flow | -186.3 | -683.15 | -266.88 | -1,195 | 1,037 | 1,150 |
Foreign Exchange Rate Adjustments | 32.37 | 45.12 | 32.82 | 279.38 | -139.91 | -262.52 |
Net Cash Flow | -910.13 | -856.72 | -1,576 | -1,364 | 1,081 | 4,685 |
Free Cash Flow | -638.84 | -433.76 | -827.62 | -1,136 | 2,093 | 3,302 |
Free Cash Flow Growth | - | - | - | - | -36.62% | - |
Free Cash Flow Margin | -17.20% | -11.22% | -19.03% | -16.10% | 30.93% | 39.32% |
Free Cash Flow Per Share | -1.54 | -1.05 | -2.01 | -2.77 | 5.08 | 8.27 |
Cash Income Tax Paid | 165.76 | 204.03 | 144.8 | 336.02 | 419.82 | 490.87 |
Levered Free Cash Flow | -910.84 | -932.68 | -467.62 | -619.14 | 1,633 | 2,799 |
Unlevered Free Cash Flow | -894.77 | -900.17 | -410.4 | -556.16 | 1,698 | 2,855 |
Change in Working Capital | -50.19 | -50.19 | -356.87 | -1,491 | 537.08 | 956.35 |
Updated Sep 30, 2025. Source: S&P Global Market Intelligence. Standard template. Financial Sources.